<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-5223-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MEXAT 25 MG/ML SOLUTION FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METHOTREXATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="INTAS PHARMACEUTICALS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            INTAS PHARMACEUTICALS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Accord Healthcare Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Mexat contains the active substance Methotrexate.<br />Methotrexate is a cytostatic substance that inhibits cell growth. Methotrexate has its<br />greatest effect on cells which increase frequently like cancer cells, bone marrow cells and<br />skin cells.<br />Mexat is used in the treatment of the following types of cancer:<br />&bull; acute lymphocytic leukaemia<br />&bull; prophylaxis of meningeal leukaemia<br />&bull; Non-Hodgkin&rsquo;s Lymphomas<br />&bull; osteogenic sarcoma<br />&bull; adjuvant and in advanced disease of breast cancer<br />&bull; metastatic or recurrent head and neck cancer<br />&bull; choriocarcinoma and similar trophoblastic diseases<br />&bull; advanced cancer of urinary bladder</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should not be given Mexat if you<br />&bull; are allergic to Methotrexate or any of the other ingredients of this medicine (listed in<br />Section 6)<br />&bull; have significant liver disease (your doctor decides the severity of your disease)<br />&bull; have significant kidney disease (your doctor decides the severity of your disease)<br />&bull; have disorders of the blood-forming system<br />&bull; have severe or existing infection such as tuberculosis and HIV<br />&bull; have ulcers in the mouth and throat or ulcers in the stomach and gut<br />&bull; are pregnant or breastfeeding (see section on Pregnancy, Breastfeeding and Fertility)<br />&bull; have increased alcohol consumption.</p><p>You should not be given live vaccines during treatment with Mexat.</p><p>Warnings and Precautions<br />&bull; Methotrexate can cause serious and sometimes life threatening undesirable effects.<br />Your doctor will talk to you about the advantages and risks of the treatment and what<br />the early signs and symptoms of undesirable effects are.<br />&bull; Methotrexate has been reported to cause foetal death and/or congenital malformations.<br />Pregnancy should be avoided if you or your partner is being treated with Methotrexate<br />(see Pregnancy, Breastfeeding and Fertility).<br />&bull; Your skin or eyes can be extremely sensitive to sunlight or other forms of light during the<br />treatment with Mexat. Therefore, sunlight and solarium should be avoided.<br />&bull; Methotrexate may cause decrease in cells responsible for providing immunity, carrying<br />oxygen, and those responsible for normal blood clotting, thereby increasing chances of<br />you getting the infections (e.g. pneumonia) or increased bleedings<br />&bull; Acute bleeding from the lungs in patients with underlying rheumatologic disease has<br />been reported with Methotrexate.<br />&bull; Methotrexate temporarily affects sperm and egg production. Methotrexate can cause<br />miscarriage and severe birth defects. You and your partner should avoid having a baby<br />if you are being given Methotrexate at the time and for at least 6 months after the end<br />of your treatment with Methotrexate. See also section &ldquo;Pregnancy, Breastfeeding and<br />Fertility&rdquo;.</p><p>Talk to your doctor, pharmacist or nurse before taking Mexat if you:<br />&bull; are to undergo radiotherapy at the same time as the Methotrexate treatment. The risk of<br />tissue and bone damage can increase with simultaneous treatment<br />&bull; are having treatment in your spine (intrathecally) or in a vein (intravenously); this can<br />cause a potentially life threatening inflammation in the brain<br />&bull; have symptoms connected to a medical condition that means that fluid is retained in<br />your body, for example in the lungs or in the abdomen<br />&bull; have impaired kidney function<br />&bull; have impaired liver function<br />&bull; have an infection<br />&bull; need to be vaccinated. Methotrexate can reduce the effect of the vaccines<br />&bull; have insulin dependent diabetes, Methotrexate treatment should be carefully<br />monitored.</p><p>Recommended follow up examinations and precautions<br />Even when Methotrexate is used at low doses, serious side effects can occur. In order to<br />recognize them in good time, your doctor must carry out checkups and laboratory tests.<br />Before the start of treatment<br />Before treatment is started, your doctor may carry out blood tests, and also to check how<br />well your kidneys and liver are working. You may also have a chest X-ray. Further tests<br />may also be done during and after treatment. Do not miss appointments for blood tests.<br />Other medicines and Mexat<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any<br />other medicines. Methotrexate affects or is affected by certain other medicinal products.<br />In particular, tell your doctor or pharmacist if you are undergoing radiotherapy or taking<br />any of the following medicines:<br />&bull; Pain and inflammation (so called NSAIDs and Salicylates)<br />&bull; Cancer (Cisplatin, Cytarabine, Mercaptopurine)<br />&bull; Infections (antibiotics such as Penicillins, Tetracycline, Ciprofloxacin and<br />Chloramphenicol)<br />&bull; Asthma (Theophylline)<br />&bull; Vitamin preparations containing Folic Acid or substances like Folic acid<br />&bull; Rheumatism (Leflunomide)<br />&bull; High blood pressure (Furosemide)<br />&bull; Gout (probenicid)<br />&bull; Radiotherapy<br />&bull; Stomach ulcers, heartburn, reflux (such as Omeprazole, Pantoprazole, Lanzoprazole)<br />&bull; Epilepsy (Phenytoin)<br />&bull; Psoriasis or severe acne (Retinoids, such as Acitretin or Isotretinoin)<br />&bull; Reumatiod arthitis or bowel disease (Sulphsalazine)<br />&bull; Rejection after an organ transplant (Azathioprine)<br />&bull; If you need to be vaccinated with a live vaccination</p><p>Mexat with food, drink and alcohol<br />During treatment with Mexat, you should not drink any alcohol and you should avoid<br />excessive consumption of coffee, soft drinks containing caffeine and black tea. Also<br />make sure you drink plenty of liquids during treatment with Mexat because dehydration<br />(reduction in body water) can increase the toxicity of Methotrexate.<br />Pregnancy, Breastfeeding and Fertility<br />Pregnancy<br />Do not use Mexat during pregnancy except if your doctor has prescribed it for oncology<br />treatment. Methotrexate can cause birth defects, harm the unborn child or cause<br />miscarriage. It is associated with malformations of the skull, face, heart and blood<br />vessels, brain, and limbs. It is therefore very important that Methotrexate is not given to<br />pregnant women or to women who are planning to become pregnant unless used for<br />oncology treatment.<br />For non-oncological indications, in women of child-bearing age the possibility of a<br />pregnancy must be ruled out, e.g. by pregnancy tests, before treatment is started.<br />Do not use Mexat if you are trying to become pregnant. You must avoid becoming<br />pregnant during treatment with Methotrexate and for at least 6 months after the end of<br />treatment. Therefore, you must ensure that you are taking effective contraception for the<br />whole of this period (see also section &quot;Warnings and Precautions&quot;).<br />If you become pregnant during treatment or suspect you might be pregnant, speak to your<br />doctor as soon as possible. If you do become pregnant during treatment, you should be<br />offered advice regarding the risk of harmful effects on the child through treatment.<br />If you want to become pregnant, you should speak with your doctor, who may refer you<br />for specialist advice before the planned start of treatment.</p><p>Male Fertility<br />The available evidence does not indicate an increased risk of malformations or<br />miscarriage if the father takes Methotrexate less than 30mg/week. However, a risk cannot<br />be completely excluded and there is no information regarding higher Methotrexate doses.<br />Methotrexate can have a genotoxic effect. This means that the medicine can cause<br />genetic mutations. Methotrexate can affect the production of sperm, which is associated<br />with the possibility of birth defects.<br />You should avoid fathering a child or to donate semen during treatment with<br />Methotrexate and for at least 6 months after the end of treatment. As treatment with<br />Methotrexate at higher doses commonly used in cancer treatment can cause infertility and<br />genetic mutations, it may be advisable for male patients treated with Methotrexate doses<br />higher than 30mg/week to consider sperm preservation before the beginning of treatment<br />(see also section &quot;Warnings and Precautions&quot;).</p><p>Methotrexate is excreted in breast milk in such quantities that there are risks of affecting<br />the baby. Breastfeeding should therefore be suspended during treatment with<br />Methotrexate.<br />Driving and using machines<br />Undesirable effects such as tiredness and dizziness may occur. If you feel tired or dizzy,<br />do not drive and do not use machines.<br />Mexat contains Sodium<br />Mexat contains 345.59mg (15.033mmol) of Sodium per maximum daily dose (1800mg).<br />To be taken into consideration by patients on a controlled Sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Mexat is given to you by healthcare professionals.<br />The dose you receive and how often you receive the dose, depend on the disease you are<br />being treated for, your state of health, your age, weight and body surface area.<br />Mexat can be given in a muscle (intramuscularly), in a vein (intravenously), in an artery<br />(intra-arterially) or in the spine (intrathecally).<br />If you are given more Mexat than you should<br />This medicine will be given to you in a hospital, under the supervision of a doctor. It is<br />unlikely that you will be given too much or too little, however, tell your doctor or nurse if<br />you have any concerns.<br />If you have any questions about your treatment, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets<br />them.<br />Mexat can have undesirable effects which may be dangerous or life threatening. During<br />the treatment, you should be alert to signs of undesirable effects and report them to your<br />doctor.<br />Contact a doctor immediately if you notice any of the following undesirable effects.<br />You may need immediate medical care.<br />&bull; Unexplained breathlessness, dry cough or wheezing (symptoms of lung problems)<br />&bull; Sudden itching, skin rash (urticaria), swollen hands, feet, ankles, face, lips, mouth or<br />throat (which can make it hard to breath and swallow). It can also feel as if you are<br />going to faint (symptoms of a severe allergic reaction)<br />&bull; Vomiting, diarrhoea or stomatitis and peptic ulcers (symptoms of effect on<br />gastrointestinal tract)<br />&bull; Yellowing of the skin or eyes, dark-coloured urine (symptoms of effect on the liver)<br />&bull; Fever, shivering, aching body and sore throat (symptoms of infection)<br />&bull; Unexpected bleeding (for example bleeding gums, dark urine, and blood in the urine or<br />vomit) or unexpected bruising, black or tar-like faeces (this can be due to a reduced<br />coagulation capacity or bleeding from the stomach or gut)<br />&bull; Skin rashes with flaking or blistering and effects on mucous membranes e.g. in the<br />nose (symptoms of Stevens-Johnsons Syndrome, toxic epidermal necrolysis and<br />erythema multiforme)<br />&bull; Abnormal behaviour, transient blindness and generalized seizures (symptoms of effect<br />on central nervous system)</p><p>Paralysis (paresis)<br />A list of undesirable effects that have been reported in treatment with Methotrexate is set<br />out below according to how common they are.<br />Very common (may affect more than 1 in 10 people)<br />&bull; loss of appetite, nausea, vomiting, abdominal pain, impaired digestion, dyspepsia<br />&bull; inflammation and ulceration in mouth and throat<br />&bull; increase in level of liver enzymes<br />Common (may affect up to 1 in 10 people)<br />&bull; herpes zoster<br />&bull; effects on the blood e.g. anaemia, leukocytopenia, thrombocytopenia<br />&bull; headache, tiredness, drowsiness<br />&bull; dry cough, shortness of breath, chest pain, fever<br />&bull; diarrhoea<br />&bull; rashes, redness and itching</p><p>Uncommon (may affect up to 1 in 100 people)<br />&bull; pancytopenia, agranulocytosis<br />&bull; inflammation of blood vessels<br />&bull; anaphylactoid reactions and allergic vasculitis<br />&bull; vertigo, confusion, depression<br />&bull; convulsions, encephalopathy<br />&bull; lymphoma (tumour in lymph tissue)<br />&bull; pulmonary fibrosis<br />&bull; bleeds and ulcers in the stomach and intestinal tract<br />&bull; inflammation of pancreas<br />&bull; liver fibrosis and cirrhosis, fatty liver<br />&bull; diabetic complications<br />&bull; reduced levels of albumin<br />&bull; skin becoming hypersensitive to sunlight, urticaria<br />&bull; hair loss, herpes zoster, painful lesions of scaly patches caused by psoriasis<br />&bull; increase of rheumatic nodules (lumps of tissues)<br />&bull; effects on skin and mucous membrane, sometimes serious (Stevens-Johnsons<br />syndrome, toxic epidermal necrolysis)<br />&bull; inflammation and ulceration of urinary bladder, haematuria, dysuria<br />&bull; inflammation and ulceration of vagina<br />&bull; brittle bones (osteoporosis), arthralgia, myalgia<br />Rare (may affect up to 1 in 1,000 people)<br />&bull; pericarditis, pericarditis effusion and tamponade<br />&bull; megaloblastic anaemia<br />&bull; mood swings<br />&bull; paresis<br />&bull; effects on speech including dysarthria and aphasia<br />&bull; myelopathy<br />&bull; visual disturbance, blurred vision<br />&bull; thrombosis (cerebral, deep vein and retinal vein)<br />&bull; low blood pressure<br />&bull; pharyngitis apnoea, bronchial asthma<br />&bull; gingivitis<br />&bull; inflammation in the small intestine<br />&bull; blood in the faeces<br />&bull; malabsorption<br />&bull; liver damage<br />&bull; acne, sores on the skin, pigment changes of the nails, bruises<br />&bull; fractures<br />&bull; renal failure, oliguria, azotaemia and anuria<br />&bull; hyperuricemia<br />&bull; elevated serum creatinine and urea level<br />&bull; abnormal development of mammary glands<br />&bull; raised blood sugar levels (Diabetes mellitus)</p><p>Very rare (may affect up to 1 in 10,000 patients)<br />&bull; infections, sepsis opportunistic infections<br />&bull; severe failure of the bone marrow, anaemia due to the fact that the bone marrow<br />cannot produce blood cells (aplastic anaemia), lymphadenopathy, lymphoproliferative<br />disorder, eosinophilia and neutropenia .<br />&bull; immunosuppression<br />&bull; hypogammaglobulinaemia<br />&bull; insomnia<br />&bull; impaired intellectual functions such as thinking, remembering and reasoning<br />&bull; joint and/or muscle pain, lack of strength<br />&bull; myasthenia (muscle weakness)<br />&bull; abnormal sensations, changes in sense of taste (metallic taste)<br />&bull; meningism (paralysis, vomiting), acute aseptic meningitis<br />&bull; conjunctivitis, retinopathy, loss of vision, puffy eye<br />&bull; inflammation of eye follicles, epiphora and photophobia<br />&bull; Tumour Lysis Syndrome<br />&bull; problem with lung function, shortness of breath, pneumonia<br />&bull; infections of lungs<br />&bull; pleural effusion<br />&bull; dilation of colon (toxic megacolon)<br />&bull; reactivation of chronic hepatitis, acute liver degeneration, Herpes simplex hepatitis,<br />liver insufficiency<br />&bull; painful swelling of skin around nail<br />&bull; expansion of small blood vessels in the skin (paronychia)<br />&bull; allergic vasculitis, hidradentis<br />&bull; proteinuria<br />&bull; loss of libido impotence<br />&bull; menstrual disorder<br />&bull; discharge from the vagina<br />&bull; infertility<br />&bull; fever, impaired wound healing<br />&bull; lymphoproliferative disorders (excessive growth of white blood cells)</p><p>Not known (frequency cannot be estimated from the available data)<br />&bull; bleeding, blood outside of vessels<br />&bull; psychosis<br />&bull; accumulation of fluid in brain and lungs<br />&bull; metabolic disorder<br />&bull; skin necrosis, exfoliative dermatitis<br />&bull; bone damage in the jaw (secondary to excessive growth of white blood cells)<br />If you receive Mexat in the spine the following undesirable effects are common (may<br />affect up to 1 in 100 patients):<br />&bull; headache<br />&bull; fever<br />&bull; inflammation in the so-called arachnoid membrane in the brain and spinal cord which<br />can cause backache, stiffness in the neck, vomiting, fever and impaired general state of<br />health; this can occur within a couple of hours after you have received Methotrexate<br />injection but usually disappears within a few days<br />&bull; hemiplegia or total paralysis, weakness in one or all extremities and cramp attacks<br />(usually occurring after repeated Methotrexate injected into the spinal cord)<br />&bull; effect on the nervous system which may start with confusion, irritation and tiredness.<br />This gets worse over time and leads to dementia (increasing loss of memory,<br />disorientation and confusion), speech difficulties, coordination and balance difficulties,<br />increased muscle stiffness, cramps and coma. This state can occur several months or<br />years after the start of treatment with Methotrexate injected into the spinal cord. The<br />condition can be life threatening; it chiefly occurs if you have large quantities of<br />Methotrexate injected into the spinal cord in combination with radiotherapy to the<br />head and/or Methotrexate in some other form.</p><p>Reporting of side effects<br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any<br />possible side effects not listed in this leaflet. You can also report side effects directly (see<br />Section 6). By reporting side effects you can help provide more information on the safety<br />of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of sight and reach of children.<br />Do not store above 25&deg;C.<br />Keep the vial in the outer carton in order to protect from light.<br />Do not use this medicine after the expiry date which is stated on the pack. The expiry<br />date refers to the last day of that month.<br />Do not use this medicine if you notice that the solution is not clear or contains particles.<br />For single-use only. Any unused solution should be discarded.<br />Chemical and physical stability of the diluted solution have been demonstrated for 24<br />hours at room temperature. For microbial point of view, the diluted solution should be<br />used immediately. If not used immediately, in-use storage times and condition prior to<br />use are the responsibility of the user.<br />Medicines should not be disposed of via wastewater or household waste. Ask your<br />pharmacist how to dispose of medicines no longer required. These measures will help to<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Mexat contains<br />The active ingredient is Methotrexate.<br />Each ml contains 25mg Methotrexate.<br />Each 2ml vial contains 50mg of Methotrexate.<br />Each 20ml vial contains 500mg of Methotrexate.<br />Each 40ml vial contains 1000mg of Methotrexate.</p><p>The other ingredients are sodium chloride, sodium hydroxide (for pH adjustment),<br />hydrochloric acid (for pH adjustment) and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Mexat is a clear yellow solution.
Pack sizes:
1×2ml vial (50mg/2ml)
1×20ml vial (500mg/20ml), 10×20ml vial (500mg/20ml)
1×40ml vial (1000mg/40ml), 10×40ml vial (1000mg/40ml)
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder (MAH):<br />Accord Healthcare Limited<br />Sage House, 319 Pinner Road, North Harrow,<br />Middlesex HA1 4HF, United Kingdom<br />Tel: +44 208 863 1427<br />Fax: +44 208 863 1426<br />E-mail: mena-info@accord-healthcare.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                08/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي ميكسات على المادة الفعالة ميثوتريكسات.<br />ميثوتريكسات عبارة عن مادة مثبّطة خلوية تعمل على تثبيط نمو الخلايا. يكون لميثوتريكسات التأثير الأكبر على<br />الخلايا التي يزداد معدل نموها بشكل متكرر مثل الخلايا السرطانية وخلايا نخاع العظم وخلايا الجلد.<br />يُستَخدَم دواء ميكسات في علاج الأنواع التالية من مرض السرطان:<br />&bull; سرطان الدم الليمفاوي الحاد<br />&bull; المعالجة الوقائية من سرطان الدم السِحائي<br />&bull; سرطان الغدد الليمفاوية اللا هودجيكينية<br />&bull; ورم خبيث يصيب العظام (ساركومة عظيمة)<br />&bull; يُستخدم هذا الدواء كعلاج مساعد (إلى جانب بعض الأدوية الأخرى) في علاج مرض سرطان الثدي في<br />المراحل المتقدمة<br />&bull; سرطان الرأس والعنق النّقيلي أو المنتكس (كثير الحدوث)<br />&bull; سرطان المشيمة وأمراض الأرومة الغاذية المماثلة<br />&bull; سرطان المثانة البولية في المراحل المتقدمة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا يجب إعطاؤك ميكسات إذا كنت<br />&bull; تعاني من حساسية تجاه ميثوتريكسات أو تجاه أيّ مكون من المكونات الأخرى الداخلة في تركيب هذا الدواء<br />( (المُدرجة في القسم رقم ٦<br />&bull; تعاني من مرض كبدي حاد (حيث يقرّر طبيبك المعالج خطورة وشدة حالتك الصحية)<br />&bull; تعاني من مرض كلوي حاد (حيث يقرّر طبيبك المعالج خطورة وشدة حالتك الصحية)<br />&bull; تعاني من اضطرابات في نظام تكوين الدّم<br />(HIV) &bull; تعاني من حالة عدوى شديدة أو قائمة مثل مرض السلّ وفيروس نقص المناعة البشرية<br />&bull; تعاني من قرحات بالفم والحلق أو قرحات بالمعدة والأمعاء<br />&bull; حاملًا أو تمارسين الرضاعة الطبيعية (انظري القسم الخاص بالحمل والرضاعة الطبيعية والخصوبة)<br />&bull; تتناول الكحوليات بكمية كبيرة<br />كما يحظر إعطاؤك لقاحات حيّة أثناء تلقي العلاج باستخدام ميكسات.<br />تحذيرات واحتياطات<br />&bull; يمكن أن يسبب ميثوتريكسات آثارًا غير مرغوبة خطيرة وفي بعض الأحيان تهدد الحياة بالخطر. سوف يتحدث<br />معك الطبيب عن فوائد ومخاطر هذا العلاج وما هي العلامات والأعراض المبكّرة لهذه الآثار غير المرغوب<br />فيها<br />&bull; تم الإبلاغ عن أن ميثوتريكسات يتسبب في وفاة الجنين و/أو حدوث تشوّهات خلْقية. يجب تجنب حدوث الحمل<br />إذا كنتِ أنتِ أو زوجكِ تتلقون علاجًا يحتوي على ميثوتريكسات (انظر القسم الخاص بالحمل والرضاعة<br />الطبيعية والخصوبة)<br />&bull; قد تصبح البشرة أو العينان حساسة للغاية لأشعة الشمس أو غيرها من أشكال الضوء أثناء تلقي العلاج<br />باستخدام ميكسات. لذلك، ينبغي تجنب التعرّض لأشعة الشمس والاستلقاء تحتها (حمام الشمس)<br />&bull; قد يسبب ميثوتريكسات انخفاضًا في عدد الخلايا المسئولة عن المناعة وحمل الأكسجين وتلك الخلايا المسئولة<br />عن تجلّط الدم بشكل طبيعي، مما يزيد من فرص إصابتك بالعدوى (مثل الالتهاب الرئوي) أو زيادة الإصابة<br />بالنزيف<br />&bull; تم الإبلاغ عن الإصابة بنزيف حاد في الرئتين في المرضى الذين يعانون من مرض الروماتيزم الكامن أثناء<br />تلقي علاجًا يحتوي على ميثوتريكسات<br />&bull; يؤثر ميثوتريكسات بشكل مؤقت على إنتاج الحيوانات المنوية لدي الرجال والبويضات لدى السيدات. يمكن أن<br />يسبب ميثوتريكسات في حدوث الإجهاض وتشوهات خلقية خطيرة. لذا يحظر على الزوج أو الزوجة التفكير<br />في الإنجاب إذا تم إعطاء أي منهما علاجًا يحتوي على ميثوتريكسات ولمدة ٦ أشهر على الأقل بعد انتهاء فترة<br />العلاج المحددة بميثوتريكسات. انظر أيضًا القسم الخاص ب &quot;الحمل، الرضاعة الطبيعية والخصوبة&quot;</p><p>تحدّث مع طبيبك المعالج، الصيدلي أو الممرض قبل أن يتم إعطائك ميكسات إذا كنت:<br />&bull; ستخضع للعلاج الإشعاعي في نفس الوقت الذي تتلقى فيه علاجًا يحتوي على ميثوتريكسات، حيث يمكن أن<br />يزداد خطر التعرّض لتلف الأنسجة والعظام في حالة العلاج المتزامن<br />&bull; تتلقى علاجًا في العمود الفقري (داخل القِراب النخاعي) أو عن طريق الحقن الوريدي (داخل الوريد)؛ فمن<br />الممكن أن يسبب ذلك التهابًا في الدماغ وقد يكون مهددًا للحياة<br />&bull; تعاني من أعراض مرتبطة بحالة مرضية تشير إلى وجود احتباس السوائل داخل الجسم، على سبيل المثال في<br />الرئتين أو البطن<br />&bull; تعاني من قصور في وظائف الكلى<br />&bull; تعاني من قصور في وظائف الكبد<br />&bull; تعاني من عدوى<br />&bull; في حاجة إلى تطعيم أو تحصين. حيث من الممكن أن يقلّل ميثوتريكسات من تأثير وفاعلية اللقاحات<br />&bull; تعاني من مرض السكّري المعتمد على العلاج بالأنسولين، فينبغي في هذه الحالة متابعة العلاج بميثوتريكسات<br />فحوصات المتابعة والاحتياطات الموصي بها<br />على الرغم من استخدام ميثوتريكسات بجرعات منخفضة، فمن الممكن أن تحدث آثار جانبية خطيرة. حيث يتعيّن<br />على طبيبك المعالج إجراء فحوصات واختبارات معملية من أجل التعرف على تلك الآثار الجانبية في الوقت<br />المناسب.<br />قبل بدء تلقي العلاج<br />قد يقوم طبيبك المعالج قبل بدء تلقي العلاج بإجراء اختبارات دم للتحقق من مدى جودة عمل الكلى والكبد. قد<br />تخضع لإجراء فحوصات الصدر من خلال جهاز التصوير بالأشعة السينية. وقد يتم أيضًا إجراء المزيد من<br />الاختبارات أثناء وبعد تلقي العلاج. يجب الالتزام بالمواعيد المحددة لإجراء اختبارات الدم.<br />تناوُل أدوية أخرى مع ميكسات<br />أخبر طبيبك المعالج أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخرًا أو قد تتناول أيّة أدوية أخرى، حيث يؤثر<br />ميثوتريكسات على فاعلية بعض الأدوية الأخرى أو العكس.<br />على وجه الخصوص، أخبر طبيبك أو الصيدلي إذا كنت تخضع للعلاج الإشعاعي أو تتناول أيًا من الأدوية<br />التالية:<br />&bull; الادوية المسكنة للألم والمضادة للالتهاب (المعروفة باسم مضادات الالتهاب غير الستيرويدية والساليسيلات)<br />&bull; أدوية علاج أمراض السرطان (سِيسْبلاتين، سيتارابين، مركابتوبورين)<br />&bull; أدوية علاج حالات العدوى (المضادات الحيوية مثل بنسلين، تتراسيكلين، سيبروفلوكساسين وكلورامفينيكول)<br />&bull; أدوية علاج مرض الربو (ثيوفيلين)<br />&bull; مستحضرات الفيتامين التي تحتوي على حمض الفوليك أو مواد مشابهة لحمض الفوليك.<br />&bull; أدوية علاج مرض الروماتيزم (ليفلونوميد)<br />&bull; أدوية علاج ارتفاع ضغط الدم (فوروسيميد)<br />&bull; أدوية علاج مرض النقرس (بروبينسيد)<br />&bull; أدوية العلاج الإشعاعي<br />&bull; أدوية علاج قرحات المعدة، حموضة المعدة، ارتجاع المريء (مثل أوميبرازول، بانتوبرازول، لانسوبرازول)<br />&bull; أدوية علاج مرض الصرع (فينيتوين)<br />&bull; أدوية علاج مرض الصدفية أو حب الشباب الشديد (الرتينويدات مثل أسيتريتين أو إيزوتريتنوين)<br />&bull; أدوية علاج مرض التهاب المفاصل الروماتويدي أو مرض الأمعاء (سلفاسالازين)<br />&bull; أدوية علاج رفض الجسم للأعضاء المزروعة(آزاثيوبرين)<br />&bull; إذا كنت في حاجة إلى تلقي أي تطعيم بلقاح حي</p><p>ميكسات مع الطعام والشراب والكحول<br />يحظر عليك شرب أية كحوليات ويتعيّن عليك تجنّب الإفراط في شرب القهوة والمشروبات الدافئة التي تحتوي<br />على الكافيين وكذلك الشاي الأسود أثناء تلقي العلاج بميكسات. ويتعيّن عليك أيضًا شرب كمية وفيرة من السوائل<br />أثناء تلقي العلاج باستخدام ميكسات حيث من الممكن أن تؤدي الإصابة بحالة جفاف (انخفاض نسبة المياه<br />بالجسم) إلى زيادة سمّية ميثوتريكسات.<br />الحمل، الرَّضاعة الطبيعية والخصوبة<br />الحمل<br />يحظر عليكِ استخدام ميكسات أثناء الحمل إلا إذا وصفه طبيبكِ المعالج لعلاج الأورام. حيث أنه من الممكن أن<br />يسبب ميثوتريكسات في حدوث تشوهات خلقية، قد يضر بالجنين أو قد يسبب الإجهاض. ويكون ذلك مصحوبًا<br />بتشوهات في الجمجمة، الوجه، القلب، الأوعية الدموية ، الدماغ والأطراف. ولذلك، من المهم جدًا عدم إعطاء<br />ميثوتريكسات للسيدات الحوامل أو اللاتي يخططن للحمل ما لم يتم استخدامه لعلاج الأورام.<br />في حالة وصف هذا الدواء لعلاج مرض غير متعلق بالأورام، يجب التأكد من عدم حمل السيدات اللاتي لديهن<br />القدرة على الحمل والإنجاب؛ مثلًا إجراء اختبارات الحمل قبل بدء تلقي العلاج.<br />يحظر عليكِ استخدام ميكسات إذا كنت تخططين للحمل. يجب عليكِ تجنب حدوث حمل أثناء تلقي علاج يحتوي<br />على ميثوتريكسات ولمدة ٦ أشهر على الأقل بعد انتهاء فترة العلاج. لذلك، يجب عليكِ التأكد من أنكِ تستعملين<br />وسائل منع حمل فعّالة طوال هذه الفترة (انظري أيضًا القسم الخاص ب &quot;تحذيرات واحتياطات&quot;).<br />أخبري طبيبكِ المعالج في أقرب وقت ممكن، إذا أصبحتِ حاملًا أو تعتقدين أنكِ حاملا أثناء العلاج بهذا الدواء.<br />يجب أن يخبركِ طبيبكِ المعالج بخطر التعرّض للآثار الضارة التي تلحق بالطفل أثناء تلقي العلاج بالدواء، إذا<br />أصبحتِ حاملًا خلال فترة تلقي العلاج.<br />إذا كنتِ ترغبين في أن تصبحين حاملًا، تحدثي إلى طبيبكِ المعالج الذي قد يحيلكِ طبيب مختص للحصول على<br />استشارة متخصصة قبل بدء العلاج المقرّر.</p><p>الخصوبة لدى الرجال<br />لا تشير الأدلة المتاحة إلى زيادة خطر التعرّض لحدوث تشوهات خلقية أو إجهاض للمرأة الحامل إذا تم إعطاء<br />الأب ميثوتريكسات بجرعة أقل من ۳۰ ملغم/أسبوعيًا. ومع ذلك، لا يمكن استبعاد الخطر تمامًا ولا توجد<br />معلومات بشأن استخدام جرعات مرتفعة من ميثوتريكسات. قد يكون لميثوتريكسات آثار سامّة للجينات. مما<br />يعني أن هذا الدواء يمكن أن يسبب حدوث طفرات جينية. ويمكن أن يؤثر ميثوتريكسات على إنتاج الحيوانات<br />المنوية لدي الرجال؛ والذي يكون مصحوبًا باحتمالية حدوث عيوب خلقية.<br />يجب تجنب إنجاب أطفال أو التبرع بالحيوانات المنوية أثناء العلاج بميثوتريكسات ولمدة ٦ أشهر على الأقل بعد<br />انتهاء فترة العلاج. حيث أن تلقي العلاج باستخدام ميثوتريكسات بجرعات مرتفعة والتي غالبًا ما تستخدم لعلاج<br />مرض السرطان يمكن أن يسبب عقم وحدوث طفرات جينية، فمن المستحسن للمرضى من الذكور الذين يتلقون<br />علاجًا بميثوتريكسات بجرعات أكثر من ۳۰ ملغم/ أسبوعيًا أن يفكروا في حفظ الحيوانات المنوية بالتجميد قبل<br />بدء تلقي العلاج (انظر أيضًا القسم تحت عنوان &quot;تحذيرات واحتياطات&quot;).<br />يفرز ميثوتريكسات في حليب الأم بكميات قد تكون هناك مخاطر لتأثيرها على الطفل. لذلك يجب إيقاف ممارسة<br />الرضاعة الطبيعية أثناء العلاج بميثوتريكسات.<br />في حالة القيادة واستخدام الآلات<br />قد تحدث آثار جانبية غير مرغوب فيها مثل الشعور بالتعب والدوخة. إذا كنت تشعر بتعب أو دوخة، تجنّب<br />القيادة واستخدام الآلات.<br />يحتوي ميكسات على الصوديوم<br />يحتوي ميكسات على ۳٤٥٫٥۹ ملغم ( ۱٥٫۰۳۳ مللي مول) من الصوديوم لكل جرعة يومية قصوى تبلغ<br />۱۸۰۰ ملغم) )<br />يجب أن يتم وضع ذلك في الاعتبار من جانب المرضى الذين يتبعون نظامًا غذائيًا مُضَبَّط (قليل) الصوديوم.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يتم إعطاؤك ميكسات من قبل أخصائي الرعاية الصحية.<br />يتم تحديد الجرعة التي تتلقاها وعدد المرات التي تتلقى فيها الجرعة حسب نوع المرض الذي يتم معالجته، حالتك<br />الصحية، عمرك، وزنك ومساحة سطح الجسم.<br />ومن الممكن إعطاء ميكسات عن طريق الحقن بالعضل (داخل العضل) أو عن طريق الحقن الوريدي (داخل<br />الوريد) أو عن طريق الشريان (داخل الشريان) أو عن طريق العمود الفقري (داخل القراب النخاعي).<br />إذا تم إعطاؤك ميكسات أكثر مما يجب<br />سيتم إعطاء هذا الدواء لك في المستشفى، تحت إشراف الطبيب. من غير المرجح أن يتم إعطاؤك الكثير أو القليل<br />جدًا، ومع ذلك، أخبر طبيبك أو ممرضك إذا كان لديك أي مخاوف.<br />استشر طبيبك المعالج أو الصيدلي إذا كانت لديك أية أسئلة أخرى حول العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يُسبب هذا الدواء، مثله مثل كافة الأدوية، آثارًا جانبية على الرغم من عدم حدوثها لدى جميع المرضى.<br />قد يكون لميكسات آثارًا غير مرغوب فيها والتي قد تكون خطيرة أو مهددة للحياة. أثناء العلاج، يجب أن تكون<br />متيقظا لأعراض هذه الآثار الجانبية غير المرغوبة وإبلاغ طبيبك المعالج بها.<br />ا من الآثار الجانبية غير المرغوبة التَّالية، حيث قد تحتاج إلى 􀌒 اتصل بطبيبك المعالج على الفور إذا لاحظت أي<br />تدخل طبي عاجل.<br />&bull; ضيق نفس غير مفسّر، سعال جاف أو أزيز بالصدر (أعراض الإصابة باضطرابات في الرئة)<br />&bull; حكّة مفاجئة، طفح جلدي (ارتيكاريا)، تورّم اليدين أو القدمين أو الكاحلين أو الوجه أو الشفتين أو الفم أو الحلق<br />(مما قد يجعل هناك صعوبة في التنفس والبلع). قد تشعر أيضًا كما لو أنك سيغمى عليك (أعراض للإصابة<br />بتفاعلات حساسية شديدة)<br />&bull; قيء، إسهال أو التهاب الفم أو قُرَح هضمية (أعراض لوجود آثار على الجهاز الهضمي)<br />&bull; اصفرار لون الجلد، العينين أو إخراج بول داكن اللون (اعراض لوجود آثار على الكبد)<br />&bull; حمّى، ارتجاف وآلام بالجسم والتهاب الحلق (أعراض للإصابة بحالة عدوى)<br />&bull; نزيف مفاجئ (على سبيل المثال نزيف اللثة، بول داكن اللون ونزول دم أثناء التبول أو التقيّؤ) أو ظهور<br />كدمات مفاجئة أو براز أسود اللون (يشبه القطران) (وقد يكون هذا بسبب انخفاض قدرة الدم على التجلّط أو<br />نزيف المعدة أو الأمعاء).</p><p>&bull; طفح جلدي مصحوب بتقشر أو تقرّحات وآثار على الأغشية المخاطية الموجودة داخل الأنف، على سبيل<br />المثال (أعراض متلازمة ستيفنز-جونسون وانحلال البشرة النخري التسممّي والحُمامَي عديدة الأشكال)<br />&bull; سلوك غير طبيعي وفقدان مؤقت للرؤية ونوبات صرع عامة (أعراض لوجود آثار على الجهاز العصبي<br />المركزي)<br />&bull; شلل (شلل جزئي)<br />فيما يلي قائمة بالآثار الجانبية غير المرغوبة والتي تم الإبلاغ عنها أثناء العلاج بميثوتريكسات وفقًا لمعدل تكرار<br />حدوثها.</p><p>آثار جانبية شائعة جدًا (قد تُؤثر على أكثر من مريض واحد من بين كل ۱۰ مرضى)<br />&bull; فقدان الشهية، غثيان، قيء، ألم بالبطن، سوء الهضم، عسر الهضم<br />&bull; التهاب ووجود قرحات داخل الفم والحلق<br />&bull; زيادة في مستوى إنزيمات الكبد<br />آثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰ مرضى)<br />&bull; هربس نطاقي (قوباء منطقية)<br />&bull; ظهور آثار على الدم مثل الإصابة بفقر الدم (الأنيميا)، قلّة كريات الدم البيضاء، قلّة الصفيحات.<br />&bull; صداع، تعب، نعاس<br />&bull; سعال جاف، ضيق التنفس، ألم بالصدر، حُمّى<br />&bull; إسهال<br />&bull; طفح جلدي، احمرار وحكّة<br />آثار جانبية غير شائعة (قد تُؤثر على ما يصل إلى مريض واحد من ببن كل ۱۰۰ مريض)<br />&bull; قلّة الكريات الشاملة (في الدم)، ندرة خلايا المحببات<br />&bull; التهاب الأوعية الدموية<br />&bull; تفاعلات فرط الحساسية والتهاب الأوعية الدموية التحسسي<br />&bull; دوار، ارتباك، اكْتِئاب<br />&bull; تشنّجات، اعتلال دماغي<br />&bull; ورم الغدد اللمفاوية (ورم في الأنسجة اللمفاوية)<br />&bull; تليف رئوي<br />&bull; نزيف وقرحات داخل المعدة والأمعاء<br />&bull; التهاب البنكرياس<br />&bull; تليّف وتشمّع الكبد، كبد دهني (تراكم الدهون على الكبد)<br />&bull; مضاعفات مرض السكر<br />&bull; انخفاض مستويات الزلال<br />&bull; تصبح البشرة شديدة الحساسية لأشعة الشمس، ارتيكاريا<br />&bull; فقدان الشعر، هربس نطاقي (قوباء منطقية)، جروح مؤلمة من بقع متقشّرة ناتجة عن الإصابة بمرض<br />الصدفية<br />&bull; زيادة العقيدات الروماتيزمية (تكتّل /تورّم الأنسجة)<br />&bull; ظهور آثار على البشرة والأغشية المخاطية، وفي بعض الأحيان تكون تلك الآثار خطيرة (متلازمة ستيفنز<br />جونسون، انحلال البشرة النخري التسممي)<br />&bull; التهاب وقرحات داخل المثانة البولية، بيلة دموية (ظهور دم في البول (، عسر/صعوبة التبوّل<br />&bull; التهاب وقرحات داخل المهبل<br />&bull; هشاشة العظام، أَلَم مَفْصِلِيّ، أَلَم عَضَلِيّ</p><p>آثار جانبية نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱,۰۰۰ مريض)<br />&bull; الْتِهابُ التَّأْمورِ (التهاب غلاف القلب)، الْتِهابُ التَّأْمورِ الانْصِبابِيّ، دُكاك أو دَحْس (حالة طبية طارئة تحدث<br />عندما يمتلئ جوف التامور بالسوائل مما يعيق حركة القلب)<br />&bull; فقر الدم ضخم الأرومات<br />&bull; تقلبات الحالة المزاجية<br />&bull; شلل جزئي<br />&bull; ظهور آثار على التحدث ويشمل ذلك التلعثموفقدان القدرة على الكلام<br />&bull; اعتلال النخاع<br />&bull; اضطراب الرؤية، عدم وضوح الرؤية<br />&bull; تجلط الدم (داخل الدماغ والوريد العميق والوريد الشبكي)<br />&bull; انخفاض ضغط الدم<br />&bull; التهاب البلعوم، انقطاع التنفس، ربو قصبي<br />&bull; التهاب اللثة<br />&bull; التهاب داخل الأمعاء الدقيقة<br />&bull; ظهور دم في البراز<br />&bull; سوء الامتصاص<br />&bull; تليّف الكبد<br />&bull; حب الشباب، تقرّحات جلدية، ظهور تغيّرات في اللون الصبغي للأظافر، كدمات<br />&bull; كسور العظام<br />&bull; فشل كلوي، قلة التبوّل، آزوتيمية/تنترج الدم، انقطاع البول<br />&bull; فرط حمض يوريك الدَّم<br />&bull; ارتفاع مستوى الكريتيانين واليوريا في مصل الدم<br />&bull; نمو غير طبيعي للغُدَدُ الثَّدْيِيَّةُ<br />&bull; ارتفاع مستويات السكر في الدم (داء السكري)</p><p>آثار جانبية نادرة جدًا (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰,۰۰۰ مريض)<br />&bull; حالات العدوى، العدوى الانتهازية الخاصة بتعفّن الدّم<br />&bull; فشل حاد في النخاع العظمي وفقر الدم الناتج عن عدم قدرة النخاع العظمي على إنتاج خلايا الدم (فقر الدم<br />اللاتنسجي)، تضخم العقد اللمفاوية، اضطراب تكاثري لمفوي، كَثْرَةُ اليُوزينِيَّات وقِلَّةُ خلايا العَدِلَات<br />&bull; تثبيط جهاز المناعة<br />&bull; نقص جاما جلوبولين الدم<br />&bull; أَرَق<br />&bull; خلل بالوظائف الفكرية مثل التفكير والتذكر والاستنتاج<br />&bull; ألم بالمفاصل و/أو بالعضلات، ضعف القوة البدنية<br />&bull; وهن عضلي (ضعف العضلات)<br />&bull; الشعور بأحاسيس غير طبيعية، تغيرات في حاسّة التذوق (الشعور بطعم معدني في الفم)<br />&bull; التهاب السحايا (شلل، قيء)، التهاب السحايا البكتيري الحاد<br />&bull; التهاب المُلتحمة، اعتلال الشبكية، فقدان الرؤية، انتفاخ العين<br />&bull; التهاب بصيلات العين وإدماع العينين، ورهاب الضوء<br />&bull; متلازمة انحلال الورم<br />&bull; اضطراب بوظائف الرئة، ضيق التنفس، التهاب رئوي<br />&bull; عدوى في الرئتين<br />&bull; انصباب جنْبي<br />&bull; انتفاخ القولون (تضخم القولون السمّي)<br />&bull; تنشيط التهاب الكبد الوبائي المزمن، تنكّس كبدي حاد، التهاب الكبد الوبائي الناتج عن الإصابة بفيروس<br />الهربس البسيط، قصور الكبد<br />&bull; تورّم مؤلم بالجلد حول الأظافر<br />&bull; تمدد الأوعية الدموية الصغيرة بالجلد (داحس)<br />&bull; التهاب الأوعية الدموية التحسسي، التهاب الغدد العرقية<br />&bull; فرط بروتينات الدم في البول<br />&bull; ضعف الرغبة الجنسية<br />&bull; اضطراب الدورة الشهرية<br />&bull; خروج إفرازات من المهبل<br />&bull; عُقم<br />&bull; حُمّى، ضعف التئام الجروح<br />&bull; اضطرابات تكاثرية لمفاوية (النمو المُفرط لخلايا الدم البيضاء)</p><p>آثار جانبية غير معروف معدّل تكرارها (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)<br />&bull; نزيف، تواجد دماء خارج الأوعية الدموية<br />&bull; ذهان<br />&bull; تراكم السوائل في الدماغ والرئتين<br />&bull; اضطراب أيضي (استقلابي)<br />&bull; نخر الجلد، التهاب الجلد التقشري<br />&bull; تلف عظام الفك (وهو عرض ثانوي للنمو المُفرط لخلايا الدم البيضاء)<br />إذا تم إعطاؤك دواء ميكسات عن طريق الحقن بالعمود الفقري (داخل القراب النخاعي)، فقد تظهر الآثار<br />الجانبية غير المرغوبة والتي قد تكون شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل ۱۰۰<br />مريض)<br />&bull; صداع<br />&bull; حُمّى<br />&bull; التهاب داخل ما يسمى بالغشاء العنكبوتي في المخ والحبل الشوكي الذي يمكن أن يسبب آلام الظهر، تصلّب<br />الرقبة، قيء، حُمى، ضعف الحالة الصحية العامّة؛ حيث يمكن أن يحدث هذا في غضون ساعتين بعد إعطاء<br />حقنة ميثوتريكسات ولكن تختفي هذه الآثار عادةً في غضون بضعة أيام<br />&bull; شلل نصفي أو شلل كلي، ضعف في أحد الأطراف أو جميعها ونوبات تقلّص عضلي (وتحدث هذه الآثار عادةً<br />بعد إعطاء ميثوتريكسات بشكل متكرّر داخل الحبل الشوكي)<br />&bull; ظهور آثار على الجهاز العصبي والتي قد تبدأ بالشعور بالارتباك، التهيّج، الإرهاق. تتفاقم هذه الأعراض<br />بمرور الوقت وتؤدي إلى الخرف (زيادة فقدان الذاكرة، التوهان والارتباك) وصعوبات في النطق، التنسيق،<br />صعوبات في توازن الجسم، زيادة تصلب العضلات، التقلّصات العضلية والغيبوبة. من الممكن أن تستمر هذه<br />الحالة من الأعراض لعدة أشهر أو سنوات بعد إعطاء حقن ميثوتريكسات التي يتم حقنها داخل الحبل الشوكي.<br />ومن الممكن أن تكون هذه الحالة مهددة للحياة؛ حيث أنها تحدث بشكل رئيسي إذا تم إعطاؤك كميات كبيرة من<br />ميثوتريكسات التي يتم حقنها داخل الحبل الشوكي بالتزامن مع تلقي علاجًا إشعاعيًا للرأس و/أو علاجًا آخر<br />يحتوي على ميثوتريكسات أيضًا<br />الإبلاغ عن الآثار الجانبية<br />تحدَّث إلى طبيبك المعالج أو الصيدلي أو الممرض، إذا أُصبت بأيّة آثار جانبية. يشمل ذلك أيّة آثار جانبية مُحتمَلة<br />غير مُدرجة في هذه النَّشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية بشكل مباشر (انظر القسم رقم ٦). ويمكنك<br />المساعدة في تقديم مزيد من المعلومات حول سلامة استخدام هذا الدَّواء من خلال الإبلاغ عن الآثار الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.<br />يحفظ في درجة حرارة أقل من ۲٥ درجة مئوية.<br />يُحفظ الفيال داخل العبوة الكرتونية الخارجية لحمايته من التعرّض للضوء.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدوّن على العبوة. حيث يُشير تاريخ انتهاء الصلاحية إلى<br />اليوم الأخير من ذلك الشهر.<br />لا تستخدم هذا الدَّواء إذا لاحظت أن المحلول غير نقي أو إذا كان يحتوي على جسيمات غريبة.<br />هذا الدواء مُعدّ للاستخدام مرة واحدة فقط. ويجب التَّخلص من أي محلول غير مُستعمل.<br />تم التأكد من الاستقرار الكيميائي والفيزيائي للمحلول المخفّف لفترة زمنية تصل إلى ۲٤ ساعة في درجة حرارة<br />الغرفة. من وجهة النظر الميكروبية (الجرثومية)، يجب استخدام المحلول المخفّف على الفور. اذا لم يتم<br />استخدامه على الفور، تقع مسئولية مراعاة مدة وظروف التخزين المعمول بها قبل الاستخدام على عاتق مُستخدم<br />الدواء.<br />لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف الصحي أو مع النفايات المنزلية. استشر الصيدلي حول<br />كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا يحتوي ميكسات<br />المادة الفعّالة هي ميثوتريكسات.<br />يحتوي كل ملليلتر على ۲٥ ملغم من ميثوتريكسات.<br />يحتوي كل فيال بسعة ۲ ملليلتر على ٥۰ ملغم من ميثوتريكسات.<br />يحتوي كل فيال بسعة ۲۰ ملليلتر على ٥۰۰ ملغم من ميثوتريكسات.<br />يحتوي كل فيال بسعة ٤۰ ملليلتر على ۱۰۰۰ ملغم من ميثوتريكسات.<br />المكوّنات الأخرى هي: كلوريد الصوديوم، هيدروكسيد الصوديوم (لضبط درجة الحموضة)، حمض<br />الهيدروكلويك (لضبط درجة الحموضة) وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو شكل ميكسات وما هي محتويات العبوة<br />ميكسات هو محلول نقي أصفر اللون.</p><p>أحجام العبوات:<br />عبوة تحتوي على عدد ۱ فيال بسعة ۲ ملليلتر ( ٥۰ ملغم / ۲ ملليلتر)<br />عبوة تحتوي على عدد ۱ فيال بسعة ۲۰ ملليلتر ( ٥۰۰ ملغم / ۲۰ ملليلتر)، عبوة تحتوي على عدد ۱۰ فيال<br />بسعة ۲۰ ملليلتر ( ٥۰۰ ملغم / ۲۰ ملليلتر)<br />عبوة تحتوي على عدد ۱ فيال بسعة ٤۰ ملليلتر ( ۱۰۰۰ ملغم / ٤۰ ملليلتر)، عبوة تحتوي على عدد ۱۰ فيال<br />بسعة ٤۰ ملليلتر ( ۱۰۰۰ ملغم / ٤۰ ملليلتر)<br />قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>لحصول على أي معلومات حول هذا الدواء أو للإبلاغ عن أي أعراض جانبية، يرجى الاتصال بالممثل المحلي<br />وحامل التصريح بالتسويق:<br />أكورد هيلثكير المكتب العلمي بالمملكة العربية السعودية<br />شركة زمو التجارية المحدودة<br />الرياض، عليا، شارع العرفج، متفرع من شارع عبدالملك بن مروان<br />خلف وزارة الداخلية، بناية أطلس، مكتب رقم ۱<br />هاتف: ۰۰۹٦٦۱۱۲۱۷۰۱٤۰<br />mena-pv@accord-healthcare.com : البريد الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            08/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mexat 25mg/ml solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 25mg Methotrexate.
One vial of 2ml of solution contains 50mg of Methotrexate
One vial of 20ml of solution contains 500mg of Methotrexate
One vial of 40ml of solution contains 100mg of Methotrexate
Excipients with known effect:
4.801mg/ml (0.208mmol/ml) Sodium.
For the full list of excipients, see Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.
Clear, yellow solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mexat is indicated in the treatment of:<br />&bull; acute lymphocytic leukaemia<br />&bull; prophylaxis of meningeal leukaemia<br />&bull; Non‐Hodgkin&rsquo;s Lymphomas<br />&bull; osteogenic sarcoma<br />&bull; adjuvant and in advanced disease of breast cancer<br />&bull; metastatic or recurrent head and neck cancer<br />&bull; choriocarcinoma and similar trophoblastic diseases<br />&bull; advanced cancer of urinary bladder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated by or occur in consultation with a doctor with significant experience in<br />cytostatic treatment.</p><p>Methotrexate can be administered intramuscularly, intravenously, intra‐arterial or intrathecally. The<br />dosage is generally calculated per m2 body surface area or body weight. Doses of over 100mg<br />Methotrexate always require subsequent administration of Folinic Acid (See Calcium Folinate<br />Rescue).<br />The application and dosage recommendations for the administration of Methotrexate for different<br />indications varies considerably. Some common dosages which have been used in different indications<br />are given below. None of these dosages can currently be described as standard therapy. Since the<br />application and dosage recommendations for therapy with Methotrexate at high and low dosages<br />vary, only the most commonly used guidelines are given. Current published protocols should be<br />consulted for dosages and the method and sequence of administration.<br />Methotrexate can be given as convention low dose therapy, intermediate dose therapy, high dose<br />therapy and intrathecal administration.<br />Conventional low dose therapy: 15‐50mg/m2 body surface area per week intravenously or<br />intramuscularly in one or more doses. 40‐60mg/m2 body surface area (for head and neck cancer)<br />once weekly as intravenous bolus injection.<br />Intermediate dose therapy: Between 100mg/m2 to 1000mg/m2 body surface area in single‐dose. In<br />advanced squamous epithelial and bladder cancer, intermediate doses of Methotrexate up to<br />100‐ 200mg/m2 can be used. (See Calcium Folinate Rescue).<br />High dose therapy: In several malignant diseases, including malignant lymphoma, acute lymphatic<br />leukaemia, osteogenic sarcoma and metastatic choriocarcinoma, doses of 1000mg Methotrexate or<br />more per m2 body surface area may be used, administered over a 24‐hour period. Administration of<br />Folinic acid must begin with 10‐15mg (6‐12mg/m2) to be given 12‐24 hours after starting<br />Methotrexate treatment (Further refer to therapy protocols, See Calcium Folinate Rescue).</p><p>Calcium Folinate Rescue<br />Since the Calcium Folinate Rescue dosage regimen depends heavily on the posology and method of<br />the intermediate or high‐dose Methotrexate administration, the Methotrexate protocol will dictate<br />the dosage regimen of Calcium Folinate Rescue. Therefore, it is best to refer to the applied<br />intermediate or high dose Methotrexate protocol for posology and method of administration of<br />Calcium Folinate.<br />In addition to Calcium Folinate administration, measures to ensure the prompt excretion of<br />Methotrexate (maintenance of high urine output and alkalinisation of urine) are integral parts of the<br />Calcium Folinate Rescue treatment. Renal function should be monitored through daily<br />measurements of serum creatinine.<br />Adults<br />Acute lymphocytic leukaemias (ALL)<br />In low doses, Methotrexate is applied within the scope of complex therapy protocols for maintaining<br />remission in adults with acute lymphocytic leukaemias. Normal single doses lie within the range of<br />20‐40mg/m2 Methotrexate. The maintenance dose for ALL is 15‐30mg/m2 once or twice weekly.<br />Other examples:<br /> 3.3mg/m2 in combination with other cytostatic agent once daily for 4‐6 week.<br /> 2.5mg/kg every week.<br /> High dose regimen between 1 to 12 g/m2 (i.v. 1‐6 h) repeated every 1‐3 weeks.<br /> 20mg/m2 in combination with other cytostatic agents once week.</p><p>Breast cancer<br />Cyclic combination with Cyclophosphamide, Methotrexate and Fluorouracil has been used as<br />adjuvant treatment to radical mastectomy in primary breast cancer with positive axillary lymph<br />nodes. The dose of Methotrexate is 40mg/m2 intravenously on the first and eighth days of the cycle.<br />The treatment is repeated at 3 week intervals. Methotrexate, in intravenous doses of 10‐60mg/m2,<br />could be included in cyclic combination regimes with other cytotoxic drugs in the treatment of<br />advanced breast cancer.<br />Osteosarcoma<br />Effective adjuvant chemotherapy requires the administration of several cytotoxic chemotherapeutic<br />drugs. In addition to high dose Methotrexate with Calcium Folinate Rescue, Doxorubicin, Cisplatin<br />and a combination of Bleomycin, Cyclophosphamide and Dactinomycin (BCD) can be given.<br />Methotrexate is used in high doses (8,000‐12,000 mg/m2) once weekly. If dose is insufficient to reach<br />real serum concentration of 10‐3 mol/L at the end of infusion, dose can be increased to 15g/m2 for<br />subsequent treatment. Calcium Folinate Rescue is necessary. Methotrexate has also been used as<br />the sole treatment in metastatic cases of osteosarcoma.<br />Older people<br />Dose reduction should be considered in elderly patient due to reduced liver and kidney function as<br />well as lower folate reserves which occur with increased age.<br />Patient with impaired renal function<br />Methotrexate should be used with caution in patients having impaired renal function. The dose<br />regimens must be adjusted according to the creatinine clearance and serum Methotrexate<br />concentrations.<br /> If creatinine clearance (ml/min) is &gt;50, 100% MTX dose can be given<br /> If creatinine clearance (ml/min) is 20‐50, 50% of MTX dose can be given<br /> If creatinine clearance (ml/min) is &lt;20, MTX should not be given<br />Patients with impaired hepatic function<br />Methotrexate should be administered with great caution, if at all, to patients with significant current<br />or previous liver disease, especially when caused by alcohol. Methotrexate is contraindicated if<br />bilirubin values are &gt;5 mg/dl (85.5 &mu;mol/L).<br />Paediatric population<br />Methotrexate should be used with caution in paediatric patients. Treatment should follow currently<br />published therapy protocols for children (see Section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mexat is contraindicated in patients who have
 Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
 Sever liver impairment (See Section 4.2).
 Alcohol abuse.
 Severe renal impairment (Creatinine clearance less than 20 ml/min, see section 4.2).
 Pre‐existing blood dyscrasias, such as bone marrow hypoplasia, leukopenia,
thrombocytopenia, or significant anaemia.
 Serious, acute or chronic infections such as tuberculosis and HIV.
 Ulcers of the oral cavity and known active gastrointestinal ulcer disease.
 Pregnancy, breast‐feeding (see section 4.6).
 Concurrent vaccination with live vaccines.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fatal toxicity in association with intravenous and intrathecal administration due to dose<br />miscalculation has been reported. Particular caution should be exercised when calculating the dose<br />( see 4.2. posology and administration).<br />Because of the risk of severe toxic reactions (which can be fatal), Methotrexate must only be used in<br />life‐threatening neoplastic diseases. Deaths have been reported during treatment of malignancies<br />with Methotrexate. The doctor should inform the patient of the risks of treatment and the patient<br />should be monitored constantly by the doctor.<br />Fertility<br />Methotrexate has been reported to cause impairment of fertility, oligospermia, menstrual<br />dysfunction and amenorrhoea in humans during and for a short period after the discontinuation of<br />treatment, affecting spermatogenesis and oogenesis during the period of its administration ‐ effects<br />that appear to be reversible on discontinuing therapy.<br />Teratogenicity &ndash; Reproductive risk<br />Methotrexate causes embryotoxicity, abortion and foetal malformations in humans. Therefore, the<br />possible effects on reproduction, pregnancy loss and congenital malformations should be discussed<br />with female patients of childbearing age (see Section 4.6). In non‐oncologic indications, the absence<br />of pregnancy must be confirmed before Mexat is used. If women of a sexually mature age are<br />treated, effective contraception must be used during treatment and for at least six months after.<br />For contraception advice for men see Section 4.6.</p><p>Tumor lysis syndrome<br />Like other cytotoxic agents, Methotrexate can induce tumour lysis syndrome in patients with rapidly<br />growing tumours. Appropriate supportive treatment and pharmacological measures can prevent or<br />alleviate such complications.<br />Methotrexate and NSAIDs<br />Unexpected severe (including fatal) myelosuppression, aplastic anaemia and gastrointestinal toxicity<br />have been reported in connection with concomitant treatment with Methotrexate (usually at a high<br />dose) and non‐steroidal anti‐inflammatory agents (NSAIDs) (See 4.5 interaction with other medicinal<br />products and other forms of interaction).<br />Concomitant Methotrexate treatment and radiotherapy can increase the risk of soft tissue necrosis<br />and osteonecrosis.<br />Intrathecal and intravenous administration of Methotrexate can result in acute encephalitis and<br />acute encephalopathy, possibly with a fatal outcome. Patients with periventricular CNS lymphoma<br />who are given Methotrexate intrathecally have reportedly developed cerebral herniation.<br />Methotrexate and pleural effusion/ascites<br />Methotrexate is eliminated slowly from collections of fluid (e.g. pleural effusion, ascites). This results<br />in a prolonged terminal half‐life and unexpected toxicity. In patients with significant collections of<br />fluid, drainage of the fluid before treatment is started and monitoring of plasma Methotrexate levels<br />are recommended.<br />If stomatitis, diarrhoea, haematemesis or black stool occurs, therapy with Methotrexate should be<br />discontinued due to the danger of haemorrhagic enteritis or death from intestinal perforation or<br />dehydration (see Section 4.8 undesirable side effects).</p><p>Conditions in which there is folic acid deficiency can increase the risk of Methotrexate toxicity.<br />In association with intrathecal administration or in high dose treatment, Methotrexate must not be<br />mixed with solutions which contain preservatives (see also 6.6).<br />Solutions of Methotrexate which contain the preservative benzyl alcohol are not recommended for<br />use in infants. Gasping syndrome with fatal outcome has been reported in infants following<br />intravenous treatment with solutions containing the preservative benzyl alcohol. Symptoms include<br />rapid onset of respiratory problems, hypotension, bradycardia and cardiovascular collapse.<br />Infection or immunological conditions<br />Methotrexate must be used with great care in connection with active infection and is usually<br />contraindicated in patients with manifest suppression of the immune response or where<br />immunodeficiency is demonstrated by laboratory tests.<br />Pneumonia (which in certain cases can lead to respiratory failure) can occur. Potentially fatal<br />opportunistic infections including Pneumocystis carinii pneumonia can occur in association with<br />methotrexate treatment. When a patient exhibits pulmonary symptoms, the possibility of<br />Pneumocystis carinii pneumonia should be considered (see Section 4.8).<br />Immunisation<br />Methotrexate may interfere with results of immunological tests. Immunisation after a vaccination<br />may be less effective in association with Methotrexate treatment.Particularly caution should be<br />exercised in the presence of inactive, chronic infections (e.g. herpes zoster, tuberculosis, hepatitis B<br />or C) due to possible activation. Immunisation with live viruses is not normally recommended.<br />Skin toxicity: Due to the risk of phototoxicity, the patient must avoid sunlight and solarium.<br />Monitoring treatment<br />Patients on Methotrexate treatment must be closely monitored so that toxic effects can be detected<br />immediately. Analyses before treatment must include a full blood count with differential and platelet<br />counts, liver enzymes, testing for hepatitis B and C infections, renal function test and x‐ray of the<br />lungs. Toxic effects of Methotrexate can occur even with low doses and therefore it is important to<br />monitor treated patients carefully. Most undesirable effects are reversible if detected early.<br />After initiation of treatment or when there is a change in the dose, or during periods in which there is<br />an increased&nbsp;risk of elevated levels of Methotrexate (e.g. in dehydration), monitoring should be<br />performed.</p><p>Bone marrow biopsy must be performed as necessary.<br />Serum Methotrexate level monitoring can significantly reduce Methotrexate toxicity and routine<br />monitoring of serum Methotrexate level is necessary depending on dosage or therapy protocol.<br />Leucopenia and thrombocytopenia occur usually 4 ‐14 days after administration of Methotrexate. In<br />rare cases recurrence of leucopenia may occur 12 ‐ 21 days after administration of Methotrexate.<br />Methotrexate therapy should only be continued if the benefit outweighs the risk of severe<br />myelosuppression (see Section 4.2).<br />Haematopoietic suppression: Haematopoietic suppression induced by Methotrexate may occur<br />abruptly and at apparently safe doses. In the event of any significant drop in leukocytes or platelets,<br />treatment must be discontinued immediately and appropriate supportive therapy instituted. Patients<br />must be instructed to report all signs and symptoms suggestive of infection. In patients</p><p>concomitantly taking haematotoxic medications (e.g. Leflunomide), the blood count and platelets<br />should be closely monitored.<br />Liver function tests: Particular attention should be paid to the onset of liver toxicity. Treatment<br />should not be initiated or should be discontinued if there are any abnormalities in liver function tests<br />or liver biopsies, or if these develop during therapy. Such abnormalities should return to normal<br />within two weeks; after which, treatment may be resumed at the discretion of the doctor. Further<br />research is needed to establish whether serial liver chemistry tests or propeptide of type III collagen<br />can detect hepatotoxicity sufficiently. This assessment should differentiate between patients without<br />any risk factors and patients with risk factors, e.g. excessive prior alcohol consumption, persistent<br />elevation of liver enzymes, history of liver disease, family history of hereditary liver disorders,<br />diabetes mellitus, obesity and previous contact with hepatotoxic drugs or chemicals and prolonged<br />Methotrexate treatment or cumulative doses of 1.5 g or more.</p><p>Screening for liver‐related enzymes in serum: A transient rise in transaminase levels to twice or three<br />times the upper limit of normal has been reported with a frequency of 13 ‐ 20%. In the event of a<br />constant increase in liver related enzymes, consideration should be given to reducing the dose or<br />discontinuing therapy.</p><p>Insulin‐dependent diabetes<br />Patients suffering from insulin‐dependent diabetes should be carefully monitored because liver<br />cirrhosis and an increase in transaminase can occur.<br />Due to the potentially toxic effect on the liver, additional hepatotoxic medications should not be<br />given during treatment with Methotrexate unless clearly necessary and alcohol consumption should<br />be avoided or greatly reduced (see Section 4.5). Closer monitoring of liver enzymes should be<br />undertaken in patients concomitantly taking other hepatotoxic medications (e.g. Leflunomide). The<br />same should also be taken into consideration if haematotoxic medications are co‐administered.<br />Malignant lymphomas may occur in patients receiving low‐dose Methotrexate; in which case,<br />Methotrexate must be discontinued. If lymphomas should fail to regress spontaneously, initiation of<br />cytotoxic therapy is required.<br />Renal function: Methotrexate treatment in patients with impaired renal function should be<br />monitored via renal function tests and urinalysis, since impaired renal function reduces the<br />elimination of Methotrexate, which may result in severe adverse reactions.<br />In cases of possible renal impairment (e.g. in elderly patients), close monitoring of renal function is<br />required. This is particularly applies to the co‐administration of medicinal products which affect<br />Methotrexate excretion cause kidney damage (e.g. non‐steroidal anti‐inflammatory drugs) or which<br />can potentially lead to haematopoietic disorder. Dehydration may also potentiate the toxicity of<br />Methotrexate. Alkalinization of the urine and increase a high diuresis is recommended.<br />Respiratory System: Acute or chronic interstitial pneumonitis, often associated with blood<br />eosinophilia, may occur and deaths have been reported. Symptoms typically include dyspnoea,<br />cough (especially a dry non‐productive cough) and fever for which patients should be monitored at<br />each follow‐up visit. Patients should be informed of the risk of pneumonitis and advised to contact<br />their doctor immediately should they develop persistent cough or dyspnoea.<br />In addition, pulmonary alveolar haemorrhage has been reported with Methotrexate used in<br />rheumatologic and related indications. This event may also be associated with vasculitis and other<br />comorbidities. Prompt investigations should be considered when pulmonary alveolar haemorrhage is<br />suspected to confirm the diagnosis.</p><p>Methotrexate should be withdrawn from patients with pulmonary symptoms and a thorough<br />investigation (including chest X‐ray) should be made to exclude infection. If Methotrexate induced<br />lung disease is suspected treatment with corticosteroids should be initiated and treatment with<br />Methotrexate should not be restarted.<br />Pulmonary symptoms require a quick diagnosis and discontinuation of Methotrexate therapy.<br />Pneumonitis can occur at all doses.<br />Vitamin preparations or other products containing Folic Acid, Folinic Acid or their derivatives may<br />decrease the effectiveness of Methotrexate.<br />Children<br />Methotrexate should be used with caution in paediatric patients. Treatment should follow currently<br />published therapy protocols for children. Serious neurotoxicity, frequently manifested as generalised<br />or focal seizures has been reported with unexpectedly increased frequency among paediatric<br />patients with acute lymphoblastic leukaemia who were treated with intermediate‐dose intravenous<br />Methotrexate (1g/m2). Symptomatic patients were commonly noted to have leukoencephalopathy<br />and/or microangiopathic calcifications on diagnostic imaging studies.<br />Elderly<br />Because of deterioration in liver and kidney function as well as reduced folic acid reserves, relatively<br />low doses should be considered in elderly patients. These patients must be closely monitored for<br />early signs of toxicity.<br />Sodium<br />Methotrexate injection contains 345.59mg (15.033 mmol) of sodium per maximum daily dose<br />(1800mg). This should be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ciprofloxacin<br />Excretion of Methotrexate possibly reduced (increased risk of toxicity).<br />Non‐steroidal anti‐inflammatory drugs (NSAIDs).<br />NSAID preparations must not be given prior to or concomitantly with the high doses of Methotrexate<br />used in the treatment of conditions such as osteosarcoma. Concomitant administration of NSAIDs<br />and Methotrexate at high doses has reportedly elevated and prolonged serum Methotrexate levels,<br />resulting in deaths from severe haematological and gastrointestinal toxicity. NSAID preparations and<br />salicylates have reportedly reduced the tubular secretion of Methotrexate in animal models and may<br />increase its toxicity by increasing Methotrexate levels. Concomitant treatment with NSAIDs and low<br />doses of Methotrexate must therefore be administered with caution.<br />Nitrous oxide<br />The use of nitrous oxide potentiates the effect of Methotrexate on folate metabolism, yielding<br />increased toxicity such as severe, unpredictable myelosuppression, stomatitis and neurotoxicity with<br />intrathecal administration. Whilst this effect can be reduced by administering Calcium Folinate, the<br />concomitant use should be avoided.<br />Leflunomide<br />Methotrexate in combination with Leflunomide can increase the risk of pancytopenia.<br />Probenecid<br />Renal tubular transport is diminished by Probenecid, and its use together with Methotrexate must be<br />avoided.</p><p>Penicillins<br />Penicillins can reduce renal clearance of Methotrexate. Haematological and gastrointestinal toxicity<br />have been observed in combination with high and low dose Methotrexate.<br />Oral antibiotics<br />Oral antibiotics such as Tetracycline, Chloramphenicol and non‐absorbable broad‐spectrum<br />antibiotics may decrease intestinal absorption of Methotrexate or interfere with the enterohepatic<br />circulation by inhibiting bowel flora and hence the metabolism of Methotrexate by bacteria. In<br />isolated cases, Trimethoprim/Sulfamethoxazole has reportedly increased myelosuppression in<br />patients treated with Methotrexate, probably due to reduced tubular secretion and/or an additive<br />antifolate effect.<br />Chemotherapeutic products<br />An increase in renal toxicity can be observed when high doses of Methotrexate are given in<br />combination with potentially nephrotoxic chemotherapeutic agents (e.g. Cisplatin).<br />Radiotherapy<br />Concurrent Methotrexate and radiotherapy can increase the risk of soft tissue necrosis and<br />osteonecrosis.<br />Cytarabine<br />Concomitant therapy with Cytarabine and Methotrexate can increase the risk of severe neurological<br />side effects ranging from headache to paralysis, coma and stroke‐like episodes.<br />Hepatotoxic products<br />The risk of increased hepatotoxicity when Methotrexate is administered concurrently with other<br />heptatotoxic products has not been studied. Hepatotoxicity has however been reported in such<br />cases. Patients receiving concomitant treatment with drugs with a known hepatotoxic effect (e.g.<br />Leflunomide, Azathioprine, Sulfasalazine, Retinoids) must be carefully monitored for signs of any<br />increase in hepatotoxicity.<br />Theophylline<br />Methotrexate can reduce clearance of Theophylline. Theophylline levels must therefore be<br />monitored during concomitant treatment with Methotrexate.<br />Mercaptopurine<br />Methotrexate increases plasma content of Mercaptopurine. The combination of Methotrexate and<br />Mercaptopurine can therefore require dose adjustment.<br />Drugs with high plasma protein binding<br />Methotrexate is partially bound to serum albumin. Other highly bound drugs such as Salicylates,<br />Phenylbutazone, Phenytoin and Sulfonamides can increase the toxicity of Methotrexate by means of<br />displacement.<br />Furosemide<br />Concomitant administration of Furosemide and Methotrexate can result in increased levels of<br />Methotrexate due to competitive inhibition of tubular secretion.<br />Vitamins<br />Vitamin preparations containing Folic Acid or its derivatives can cause a reduced response to<br />systemically administered Methotrexate, however conditions in which there is a deficiency of Folic<br />Acid can increase the risk of Methotrexate toxicity.</p><p>Proton Pump Inhibitors<br />Literature data indicate that co‐administration of proton pump inhibitors and Methotrexate,<br />especially at high dose, may result in elevated and prolonged plasma levels of Methotrexate and/or<br />its metabolite, possibly leading to Methotrexate toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential/Contraception in females<br />Women must not get pregnant during Methotrexate therapy, and effective contraception must be<br />used during treatment with Methotrexate and at least 6 months thereafter (see Section 4.4). Prior to<br />initiating therapy, women of childbearing potential must be informed of the risk of malformations<br />associated with Methotrexate and any existing pregnancy must be excluded with certainty by taking<br />appropriate measures, e.g. a pregnancy test. During treatment pregnancy tests should be repeated<br />as clinically required (e.g. after any gap of contraception). Female patients of reproductive potential<br />must be counselled regarding pregnancy prevention and planning.<br />Contraception in males<br />It is not known if Methotrexate is present in semen. Methotrexate has been shown to be genotoxic<br />in animal studies, such that the risk of genotoxic effects on sperm cells cannot completely be<br />excluded. Limited clinical evidence does not indicate an increased risk of malformations or<br />miscarriage following paternal exposure to low‐dose Methotrexate (less than 30mg/week). For<br />higher doses, there is insufficient data to estimate the risks of malformations or miscarriage<br />following paternal exposure.<br />As precautionary measures, sexually active male patients or their female partners are recommended<br />to use reliable contraception during treatment of the male patient and for at least 6 months after<br />cessation of Methotrexate. Men should not donate semen during therapy or for 6 months following<br />discontinuation of Methotrexate.<br />Pregnancy<br />Methotrexate is contraindicated during pregnancy in non‐oncological indications (see Section 4.3). If<br />pregnancy occurs during treatment with Methotrexate and up to six months thereafter, medical<br />advice should be given regarding the risk of harmful effects on the child associated with treatment<br />and ultrasonography examinations should be performed to confirm normal foetal development. In<br />animal studies, Methotrexate has shown reproductive toxicity, especially during the first trimester<br />(see Section 5.3). Methotrexate has been shown to be teratogenic to humans; it has been reported<br />to cause foetal death, miscarriages and/or congenital abnormalities (e.g. craniofacial, cardiovascular,<br />central nervous system and extremity‐related).</p><p>Methotrexate is a powerful human teratogen, with an increased risk of spontaneous abortions,<br />intrauterine growth restriction and congenital malformations in case of exposure during pregnancy.<br />&bull; Spontaneous abortions have been reported in 42.5% of pregnant women exposed to low‐dose<br />Methotrexate treatment (less than 30mg/week), compared to a reported rate of 22.5% in diseasematched<br />patients treated with drugs other than Methotrexate.<br />&bull; Major birth defects occurred in 6.6% of live births in women exposed to low‐dose Methotrexate<br />treatment (less than 30mg/week) during pregnancy, compared to approximately 4% of live births in<br />in disease‐matched patients treated with drugs other than Methotrexate.<br />Insufficient data is available for Methotrexate exposure during pregnancy higher than 30mg/week,<br />but higher rates of spontaneous abortions and congenital malformations are expected, in particular<br />at doses commonly used in oncologic indications<br />When Methotrexate was discontinued prior to conception, normal pregnancies have been reported.</p><p>When used in oncological indications, Methotrexate should not be administered during pregnancy in<br />particular during the first trimester of pregnancy. In each individual case the benefit of treatment<br />must be weighed up against the possible risk to the foetus. If the drug is used during pregnancy or if<br />the patient becomes pregnant while taking Methotrexate, the patient should be informed of the<br />potential risk to the foetus.<br />Breastfeeding<br />Methotrexate passes into breast milk in quantities such that there is a risk to the child even at<br />therapeutic doses. Breast feeding must therefore be discontinued during treatment with<br />Methotrexate.<br />Fertility<br />Methotrexate affects spermatogenesis and oogenesis and may decrease fertility. In humans,<br />Methotrexate has been reported to cause oligospermia, menstrual dysfunction and amenorrhoea.<br />These effects appear to be reversible after discontinuation of therapy in most cases. In oncologic<br />indications, women who are planning to become pregnant are advised to consult a genetic<br />counselling centre, if possible, prior to therapy and men should seek advice about the possibility of<br />sperm preservation before starting therapy as Methotrexate can be genotoxic at higher doses<br />(see Section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since fatigue and dizziness can occur as an undesirable effect, ability to react and judgement can be<br />impaired, which should be taken into account for example when driving or carrying out work<br />involving a high degree of precision.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Conventional and high dose therapy<br />The frequency and degree of severity of undesirable effects depends on the dose administered, the<br />duration of exposure and method of administration, but side effects have been seen at all doses and<br />can occur at any time during treatment. Most undesirable effects are reversible when detected at an<br />early stage. When severe reactions occur, the dose should be reduced or treatment discontinued and<br />appropriate measures initiated (See 4.9). If treatment with Methotrexate is resumed, this should be<br />done with caution after adequate consideration of the further need for the drug. Increased vigilance<br />with regard to any recurrence of toxicity is required.<br />The most frequently reported undesirable effects include ulcerative stomatitis, leukopenia, nausea<br />and bloating. Other frequently reported undesirable effects are feeling unwell, unusual tiredness,<br />chills and fever, dizziness, reduced resistance to infections. Treatment with Folinic acid during high<br />dose therapy can counteract or alleviate a number of undesirable effects. Temporary discontinuation<br />of therapy is recommended if there are signs of leukopenia.</p><p>The following undesirable effects have also been reported, but their frequency has not been<br />established: Pneumocystis carinii pneumonia, (including reversible cases), foetal death, damage to<br />the foetus, abortion.<br />Systemic organ toxicity<br />Lymphoma<br />Malignant lymphoma which can go into remission after discontinuation of the treatment with<br />Methotrexate can occur in patients on low dose therapy, and may not therefore require any<br />cytotoxic treatment. Methotrexate should be discontinued first and appropriate treatment initiated<br />if the lymphoma does not regress.<br />Haematological<br />Methotrexate can suppress haematopoiesis and cause anaemia, aplastic anaemia, pancytopenia,<br />leukopenia, neutropenia and/or thrombocytopenia. Methotrexate must be administered with<br />caution to patients with malignancies and underlying factors affecting haematopoiesis. When<br />treating neoplastic conditions, treatment with Methotrexate should only be given provided the<br />potential benefits outweigh the risk of myelosuppression.</p><p>Lungs<br />Lung disease caused by Methotrexate, including acute or chronic interstitial pneumonitis, is a<br />potentially dangerous complication, which can occur at any time during the course of treatment. This<br />undesirable effect has been reported at low doses and is not always totally reversible. Deaths have<br />been reported. Signs of pulmonary involvement or symptoms such as dry non‐productive cough,<br />fever, chest pains, dyspnoea, hypoxemia and infiltrate on X‐ray of the lungs, or non‐specific<br />pneumonitis which occurs in connection with Methotrexate therapy, may indicate potentially serious<br />damage and requires discontinuation of treatment and careful investigation. Lung changes can occur<br />at all doses. The possibility of infection (including pneumonia) must be excluded.<br />Gastrointestinal<br />If vomiting, diarrhoea or stomatitis occur, with resulting dehydration, Methotrexate therapy must be<br />discontinued until the patient has recovered. Haemorrhagic enteritis and deaths caused by intestinal<br />perforation can occur. Methotrexate must be used with great caution in patients with peptic ulcers<br />or ulcerative colitis. Stomatitis can be prevented or alleviated by Folinic Acid mouthwashes.<br />Liver<br />Methotrexate involves a potential risk of acute hepatitis and chronic (fibrosis and cirrhosis)<br />hepatotoxicity. Chronic toxicity is potentially fatal and occurs commonly after long‐term use (in<br />general after 2 years or more) and after a total cumulative dose greater than 1.5g. In studies of<br />psoriasis patients hepatotoxicity was seen to be proportional to the cumulative dose and was<br />potentiated by alcoholism, overweight, diabetes and age.<br />Transient deterioration in liver enzyme values is frequently seen after Methotrexate treatment and<br />does not usually necessitate adjustment of treatment. Existing abnormal liver values and/or<br />reduction in serum albumin can indicate severe hepatotoxicity.<br />Methotrexate has caused reactivation of hepatitis B infections and exacerbation of hepatitis C<br />infections, in some cases with fatal outcome. Some cases of hepatitis B reactivation have occurred<br />following discontinuation of Methotrexate. Clinical and laboratory tests should be performed to<br />investigate any occurrence of liver disease in patients with prior hepatitis B or C infections. Based on<br />these investigations, treatment with Methotrexate may prove unsuitable for certain patients.<br />In the event of impaired liver function, the undesirable effects of Methotrexate (in particular<br />stomatitis) can be exacerbated.</p><p>Kidneys<br />Methotrexate can cause kidney damage which can result in acute renal failure. Renal function can be<br />exacerbated following high dose therapy to such an extent that the excretion of Methotrexate is<br />inhibited, as a result of which systemic Methotrexate toxicity can occur. In order to prevent renal<br />failure, alkalinization of the urine and adequate fluid intake (at least 3 l/day) are recommended.<br />Measurement of serum Methotrexate and renal function is recommended.<br />Skin<br />Serious, in some cases fatal skin reactions, including toxic epidermal necrolysis (Lyell&rsquo;s syndrome),<br />Stevens‐Johnson syndrome and erythema multiforme have been reported within a few days of oral,<br />intramuscular, intravenous or intrathecal treatment with Methotrexate in single or repeat doses.<br />Radiation dermatitis and sunburn can be accentuated after use of Methotrexate.<br />CNS<br />There are reports of leukoencephalopathy after intravenous treatment with Methotrexate in<br />patients who have undergone craniospinal radiotherapy. Severe neurotoxicity, often manifested as<br />generalised or focal seizures have been reported with an unexpected increase in frequency in<br />children with acute lymphoblastic leukaemia treated with a moderately high dose of intravenous<br />methotrexate (1 g/m2). Symptomatic patients frequently had leukoencephalopathy and/or<br />microangiopathic calcifications in X‐ray investigations.</p><p>Chronic leukoencephalopathy has also been reported in patients treated with repeated high doses of<br />Methotrexate together with Folinic Acid, even without concomitant cranial radiotherapy.<br />Discontinuation of the Methotrexate therapy did not always result in full recovery.<br />Leukoencephalopathy has also been reported in patients treated with Methotrexate tablets.<br />One transient acute neurological syndrome has been observed in patients undergoing high dose<br />therapy. Manifestations of this neurological syndrome can include abnormal behaviour, focal<br />sensorimotor symptoms including transient blindness, and abnormal reflexes. The exact cause is<br />unclear.<br />Cases of neurological side effects ranging from headache to paralysis, coma and stroke‐like episodes<br />have been reported, primarily in children and adolescents receiving concomitant medication with<br />Cytarabine.<br />Intrathecal therapy<br />The subacute neurotoxicity is usually reversible after discontinuing Methotrexate.</p><p>Chemical arachnoiditis, which can occur a few hours after intrathecal administration of Methotrexate<br />is characterised by headache, back pain, stiff neck, vomiting, fever, meningism and pleocytosis in the<br />cerebrospinal fluid similar to that in bacterial meningitis. Arachnoiditis generally disappears within a<br />few days.<br />Subacute neurotoxicity, common after frequently repeated intrathecal administration, mainly affects<br />the motor functions in the brain or spinal cord. Paraparesis/paraplegia, with involvement of one or<br />more spinal nerve roots, tetraplegia, cerebellar dysfunction, cranial nerve paralysis and epileptic<br />seizures can occur.<br />Necrotising demyelinating leukoencephalopathy can occur several months or years after starting<br />intrathecal therapy. The condition is characterized by progressive neurological deterioration with<br />insidious onset, confusion, irritability and somnolence. Ultimately severe dementia, dysarthria,<br />ataxia, spasticity, seizures and coma can occur. The condition can be fatal. Leukoencephalopathy<br />occurs primarily in patients who have received large quantities of intrathecal Methotrexate in<br />combination with cranial radiotherapy and/or systemically administered Methotrexate.<br />Signs of neurotoxicity (meningeal inflammation, transient or permanent paresis, encephalopathy)<br />must be followed up after intrathecal administration of Methotrexate.</p><p>To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; Fax: +966‐11‐205‐7662<br />&bull; SFDA call center 19999<br />&bull; Toll free phone: 8002490000<br />&bull; E‐mail: npc.drug@sfda.gov.sa<br /> Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>treatment, although overdose in association with intravenous and intramuscular administration has<br />also been reported.<br />Reports of oral overdose have often been due to accidental daily instead of weekly ingestion.<br />Commonly reported symptoms following oral overdose include the symptoms and signs seen at<br />pharmacological doses, in particular haematological and gastrointestinal reactions such as<br />leukopenia, thrombocytopenia, anaemia, pancytopenia, neutropenia, myelosuppression, mucositis,<br />stomatitis, oral ulceration, nausea, vomiting, gastrointestinal ulceration, gastrointestinal bleeding. In<br />certain cases no symptoms were reported. There are reports of deaths associated with overdose. In<br />these cases there were also reports of conditions involving sepsis or septic shock, renal failure and<br />aplastic anaemia.<br />The most common symptoms of intrathecal overdose are CNS symptoms including headache, nausea<br />and vomiting, seizures or convulsions and acute toxic encephalopathy. In certain cases, no symptoms<br />were reported. There have been reports of deaths following intrathecal overdose. In these cases<br />there were also reports of cerebellar herniation accompanying elevated intracranial pressure and<br />toxic encephalopathy.<br />Recommended treatment<br />Antidote therapy: Folinic acid should be given parenterally at a dose at least the size of the<br />Methotrexate dose and should wherever possible be administered within an hour. Folinic Acid is<br />indicated to minimize toxicity and counter the effect of Methotrexate overdose. Folinic Acid<br />treatment should be initiated as soon as possible. The longer the interval between the administration<br />of Methotrexate and the initiation of Folinic Acid, the less the effect of Folinic Acid in suppressing the<br />toxic effect. Monitoring of serum Methotrexate concentrations is necessary to be able to determine<br />the optimum dose of Folinic Acid and the length of the treatment.<br />In the event of a major overdose, hydration and alkalinization of&nbsp;the urine may be required to<br />prevent precipitation of Methotrexate and/or its metabolites in the renal tubules. Neither standard<br />haemodialysis nor peritoneal dialysis have been shown to increase the elimination of Methotrexate.<br />Acute intermittent haemodialysis with the use of highly permeable dialyser may be attempted for<br />Methotrexate intoxication.<br />Intrathecal overdose may require intensive systemic supportive measures such as systemic<br />administration of high doses of Folinic Acid, alkaline diuresis, acute CSF drainage and ventricular<br />lumbar perfusion.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Cytostatic agent: Folic Acid analogue<br />ATC code: L01BA01<br />Methotrexate is a Folic Acid antagonist with a cytostatic effect. Methotrexate inhibits the conversion<br />of folic acid to Tetrahydrofolic Acid since the compound has a greater affinity for the enzyme<br />Dihydrofolate reductase than the natural substrate folic acid. As a result, DNA synthesis and new cell<br />formation are inhibited. Methotrexate is s‐phase specific. Actively proliferating tissues such as<br />malignant cells, bone marrow, foetal cells, epithelium and buccal and intestinal mucosa are generally<br />most susceptible to Methotrexate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following intravenous administration, peak serum concentrations of Methotrexate are reached after<br />approx. 0.5 &ndash; 1 hour. There is wide inter‐individual and intra‐individual variation, especially with<br />repeated doses. Saturation of oral absorption occurs at doses above 30mg/m2. About half of the<br />absorbed Methotrexate is bound to plasma proteins, but binding is reversible, and Methotrexate is<br />easily diffused into the cells, with the highest concentrations reached in the liver, spleen and kidneys<br />in the form of polyglutamate can be found which can be retained for few weeks or months.<br />Methotrexate also passes to a lesser degree into cerebrospinal fluid. The half‐life is approx. 3 to 10<br />hours with low dose therapy and approx. 8 to 15 hours with high dose therapy. Elimination from<br />plasma is triphasic and the majority of the Methotrexate is excreted unchanged in urine within 24<br />hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies show that Methotrexate impairs fertility and that it is embryotoxic, foetotoxic and<br />teratogenic. Methotrexate is mutagenic in vivo and in vitro, but the clinical significance is unknown<br />since rodent carcinogenicity studies have produced differing results. Chronic toxicity studies in mice,<br />rats and dogs showed toxic effects in the form of gastrointestinal lesions, myelosuppression and<br />hepatotoxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride<br />Sodium hydroxide (For pH adjustment)<br />Hydrochloric acid (For pH adjustment)<br />Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Owing to the absence of compatibility studies, this medicine should not be mixed with other<br />medicines except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life of unopened vial:
24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep this medicine out of sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the pack. The expiry date refers to<br />the last day of that month.<br />Do not store above 25&deg;C.<br />Keep the vial in the outer carton in order to protect from light.<br />Do not use this medicine if you notice that the solution is not clear or contains particles.<br />For storage conditions of the diluted medicinal product, see Section 6.3.<br />For single‐use only. Any unused solution should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mexat 25mg/ml solution for injection is filled in Type‐I glass vial sealed with rubber stopper and<br />aluminium flip‐off cap.<br />Pack sizes:<br />1&times;2ml vial (50mg/2ml)<br />1&times;20ml vial (500mg/20ml), 10&times;20ml vial (500mg/20ml)<br />1&times;40ml vial (1000mg/40ml), 10&times;40ml vial (1000mg/40ml)<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution should be visually inspected prior to use. Only clear solution practically free from&nbsp;particles should be used.<br />Mexat may be further diluted with an appropriate preservative‐free medium such as Glucose<br />Solution (5%) or Sodium Chloride Solution (0.9%).<br />With respect to the handling the following general recommendations should be considered: The<br />product should be used and administered only by trained personnel; the mixing of the solution<br />should take place in designated areas, designed to protect personnel and the environment (e.g safety<br />cabins); protective clothing should be worn (including gloves, eye protection, and masks if<br />necessary).<br />Pregnant healthcare personnel should not handle and/or administer Metotrexat.</p><p>Methotrexate should not come into contact with the skin or mucosa. In the event of contamination,<br />the affected area must be irrigated immediately with copious quantities of water at least ten<br />minutes.<br />For single‐use only. Any unused solution should be discarded. Waste should be disposed of carefully<br />in suitable separate containers, clearly labelled as to their contents (as the patient&#39;s body fluids and<br />excreta may also contain appreciable amounts of antineoplastic agents and it has been suggested<br />that they, and material such as bed linen contaminated with them, should also be treated as<br />hazardous waste). Any unused product or waste should be disposed of in accordance with local<br />requirements by incineration.<br />Adequate procedures should be in place for accidental contamination due to spillage; staff exposure<br />to antineoplastic agents should be recorded and monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accord Healthcare Limited
Sage House, 319, Pinner Road
North Harrow
Middlesex HA1 4HF
United Kingdom
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>